drugset / Trial / NCT01051882

Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.

NCT01051882 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study will evaluate the safety, tolerability and therapeutic effects (preliminary efficacy) of injection of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), as a possible treatment for patients with Amyotrophic Lateral Sclerosis (ALS) at the early and progressive disease stages.

Timeline

Start
2011-06
Primary completion
2012-12
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject MSC-NTF cells Cell therapy 24 cells Intramuscular
Subject MSC-NTF cells Cell therapy 60 cells Intramuscular